Eli Lilly has signed an agreement with therapeutics company Anima Biotech to discover and develop translation inhibitor drugs for proteins related to a variety of difficult-to-treat diseases.
Anima Biotech announced an agreement with Lilly for the discovery and development of translation inhibitors for several target proteins by using Anima's Translation Control Therapeutics platform.